Science ❯ Psychopharmacology ❯ Psychedelics ❯ Therapeutic Effects
More than half of cancer patients in the Phase II trial experienced sustained remission of depressive symptoms with a single dose of psilocybin, prompting researchers to launch repeat-dose studies.
